Oncoclínicas do Brasil Serviços Médicos (ONCO3) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
17 Aug, 2026Executive summary
Faced significant operational and financial headwinds in Q2 2026, including a drug/medication supply crisis, liquidity constraints, and cash flow pressures, but maintained care quality and advanced restructuring and cost optimization initiatives.
Implemented a R$150 million private financing agreement to stabilize medicine supply and engaged in creditor negotiations to realign debt amortization and strengthen financial capacity.
Non-recurring accounting adjustments, including credit loss provisions, impairments, and contract termination penalties, significantly affected results.
Entered judicial recovery in July 2026 to restructure approximately R$5.1 billion in financial debt, with all debt reclassified as short-term due to covenant breaches.
Continued focus on sustainable growth, profitability, and transparent communication with the market.
Financial highlights
Gross revenue for Q2 2026 was R$1,227.6 million, down 25.9% year-over-year; net revenue was R$1,047.7 million, down 28.5% year-over-year, mainly due to medication shortages and asset sales.
Adjusted EBITDA for Q2 2026 was R$34.3 million (margin 9.5% excluding PCLD), but only R$34.2 million (margin 3.3%) including all effects; net loss for the quarter was R$475.7 million, with net loss ex-hospitals at R$425 million.
Gross margin, excluding non-recurring effects, was 27.2%; accounting gross margin was 21.9%–22.2%.
Cash flow from operations was positive at R$158.4 million, mainly due to renegotiated supplier terms and normalization of receivables.
Net debt at quarter-end was R$3.4 billion, with total debt at R$3,686.7 million and cash position at R$129.0–R$160.9 million.
Outlook and guidance
Recovery is expected to be gradual, with ongoing discipline in executing the restructuring plan, cost optimization, and asset divestitures to restore profitability and liquidity.
Management remains focused on operational turnaround, considering inorganic initiatives and further operational adjustments.
Judicial recovery aims to provide a stable environment for debt renegotiation and operational continuity.
Latest events from Oncoclínicas do Brasil Serviços Médicos
- Revenue and profitability declined sharply amid operational and financial pressures.ONCO3
Q1 2026 - Net loss hit R$3.67 billion amid defaults, liquidity stress, and major restructuring actions.ONCO3
Q4 2025 - Adjusted EBITDA rose 30.4% QoQ as operational efficiency offset revenue declines.ONCO3
Q3 2025 - Adjusted EBITDA rose 38.3% sequentially, but net loss and leverage increased amid restructuring.ONCO3
Q2 2025 - Revenue and cash flow surged, but net income fell on higher taxes and restructuring costs.ONCO3
Q3 2024 - Gross revenue up 16%, leverage down to 2.5x, and first international JV announced.ONCO3
Q2 2024 - Revenue growth slowed and margins compressed, but cash flow and working capital improved.ONCO3
Q1 2025 - Revenue up 13.5% in 2024, but net loss of R$717M due to impairment and higher costs.ONCO3
Q4 2024